Pharmaceutical Executive Europe - June 2008 - (Page 21) Pharmaceutical Executive Europe June 2008 Special Report 21 Darryl Leniuk/Getty Images being entrepreneurs evaluate themselves, and how do investors evaluate the aspiring academic entrepreneur? The key is education and business knowledge. An academic who has the right training and experience, who understands the issues and challenges, and who can conceptualise the commercial goal and fix a course is the ideal partner for the professional managers who are experts in teamwork, finance and legal, and so on. But professional managers face an inordinate disadvantage in the life sciences world because they are rarely competent in the potential and the pitfalls of the science involved. In our experience the potentially successful academic entrepreneur is recognisable because he has communication skills and a business vocabulary. The business professionals who want to partner with such a rare beast will have the ability to groom the academic for their exit in such a way that the academic can see the added value the professional business managers bring. In the UK we have excellent scientists and academics, but we’re not very good at helping them to exploit their knowledge. What we need are more business people with scientific expertise who can recognise commercial opportunities and have the right contacts with the financial community and industry to help bring such opportunities to the market. And most of all we need academics who not only aspire to be entrepreneurs, but who also have the background and training to be successful. About the Author David Wallder is chief executive officer and founded of Wallder Consulting Ltd, an executive search firm specialising in building senior management teams in the life sciences industry. David has over 25 years’ experience of management consulting and recruitment. He is also a Fellow of both the Royal Society of Medicine and the Chartered Institute of Personnel Development. He can be contacted at david@wallder.com http://www.wallder.com
Table of Contents Feed for the Digital Edition of Pharmaceutical Executive Europe - June 2008 Pharmaceutical Executive Europe - June 2008 Contents From the Editor News and Analysis Calendar Brussels Report - Tell Us Something We Didn’t Know BioFutures - Friends, Acquaintances and Strangers IT Matters - The High Cost of Swimming Upstream Strategy Fundamentals - Hidden in Books Corporate Strategy - New Dimensions for New Business Models Special Report: Making the Leap Sales Force Incentives - The Goal: Setting Goals Last Word Pharmaceutical Executive Europe - June 2008 Pharmaceutical Executive Europe - June 2008 - Pharmaceutical Executive Europe - June 2008 (Page Cover1) Pharmaceutical Executive Europe - June 2008 - Pharmaceutical Executive Europe - June 2008 (Page Cover2) Pharmaceutical Executive Europe - June 2008 - Contents (Page 3) Pharmaceutical Executive Europe - June 2008 - From the Editor (Page 4) Pharmaceutical Executive Europe - June 2008 - From the Editor (Page 5) Pharmaceutical Executive Europe - June 2008 - News and Analysis (Page 6) Pharmaceutical Executive Europe - June 2008 - News and Analysis (Page 7) Pharmaceutical Executive Europe - June 2008 - Calendar (Page 8) Pharmaceutical Executive Europe - June 2008 - Brussels Report - Tell Us Something We Didn’t Know (Page 9) Pharmaceutical Executive Europe - June 2008 - BioFutures - Friends, Acquaintances and Strangers (Page 10) Pharmaceutical Executive Europe - June 2008 - IT Matters - The High Cost of Swimming Upstream (Page 11) Pharmaceutical Executive Europe - June 2008 - IT Matters - The High Cost of Swimming Upstream (Page 12) Pharmaceutical Executive Europe - June 2008 - Strategy Fundamentals - Hidden in Books (Page 13) Pharmaceutical Executive Europe - June 2008 - Corporate Strategy - New Dimensions for New Business Models (Page 14) Pharmaceutical Executive Europe - June 2008 - Corporate Strategy - New Dimensions for New Business Models (Page 15) Pharmaceutical Executive Europe - June 2008 - Corporate Strategy - New Dimensions for New Business Models (Page 16) Pharmaceutical Executive Europe - June 2008 - Corporate Strategy - New Dimensions for New Business Models (Page 17) Pharmaceutical Executive Europe - June 2008 - Special Report: Making the Leap (Page 18) Pharmaceutical Executive Europe - June 2008 - Special Report: Making the Leap (Page 19) Pharmaceutical Executive Europe - June 2008 - Special Report: Making the Leap (Page 20) Pharmaceutical Executive Europe - June 2008 - Special Report: Making the Leap (Page 21) Pharmaceutical Executive Europe - June 2008 - Sales Force Incentives - The Goal: Setting Goals (Page 22) Pharmaceutical Executive Europe - June 2008 - Sales Force Incentives - The Goal: Setting Goals (Page 23) Pharmaceutical Executive Europe - June 2008 - Sales Force Incentives - The Goal: Setting Goals (Page 24) Pharmaceutical Executive Europe - June 2008 - Last Word (Page 25) Pharmaceutical Executive Europe - June 2008 - Last Word (Page 26) Pharmaceutical Executive Europe - June 2008 - Last Word (Page 27)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.